
Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals
Keywords: Simulation Model; Sofosbuvir; Health Economics; DAA; oral direct-acting antiviral; HCV; hepatitis C virus; ICER; incremental cost-effectiveness ratio; LT; liver transplantation; MELD; Model for End-stage Liver Disease; QALY; quality-adjusted life year; SV